Charles River Laboratories International, Inc. (NYSE: CRL) Investor Investigation Over Potential Securities Laws Violations Announced

Investors who purchased shares of Charles River Laboratories International, Inc. (NYSE: CRL), have certain options and should contact the Shareholders Foundation, Inc.

To have your information reviewed for options and to recieve notifications about this investigation, please use this form. You may also send an email to mail@shareholdersfoundation.com, or call us at (858) 779-1554.
Company Name(s): 
Charles River Laboratories
Affected Securities: 
NYSE: CRL

An investigation on behalf of investors of Charles River Laboratories International, Inc. (NYSE: CRL) shares over potential securities laws violations by Charles River Laboratories International, Inc. and certain of its directors and officers in connection with certain financial statements was announced.

The investigation by a law firm focuses on possible claims on behalf of purchasers of the securities of Charles River Laboratories International, Inc. (NYSE: CRL) concerning whether a series of statements by Charles River Laboratories International, Inc. regarding its business, its prospects and its operations were materially false and misleading at the time they were made.

Wilmington, MA based Charles River Laboratories International, Inc., an early-stage contract research company, provides drug discovery, non-clinical development, and safety testing services worldwide. Charles River Laboratories International, Inc. reported that its annual Total Revenue rose from over $1.85 billion in 2017 to over $2.26 billion in 2018 and that its Net Income increased from $123.35 million in 2017 to $226.37 million in 2018.

On April 30, 2019, Charles River Laboratories International, Inc disclosed that a “highly sophisticated, well-resourced intruder” accessed its information system in mid-March 2019, and that data belonging to “approximately 1% of Charles River’s total number of clients” was “known to have been copied”.

Shares of Charles River Laboratories International, Inc. (NYSE: CRL) declined on May 2, 2019 to $136.24 per share.